

Texas Department of State Health Services
Drug-Resistant Tuberculosis Monitoring Program
 Case Conference Presentation Summary

New Patient Information

Surveillance Event #:		Age/Gender:	
Site and Type of Disease: <input type="checkbox"/> Suspected <input type="checkbox"/> Confirmed <input type="checkbox"/> Pulmonary <input type="checkbox"/> Extrapulmonary, site: <input type="checkbox"/> RR <input type="checkbox"/> MDR <input type="checkbox"/> Pre-XDR <input type="checkbox"/> XDR <input type="checkbox"/> Intolerant/Functional			
ATS Class 3 Date:		Referred by: _____ Date: _____ Date first evaluated by HD: _____	
Date of U.S. Arrival: _____ <input type="checkbox"/> EDN <input type="checkbox"/> Refugee <input type="checkbox"/> Tourist <input type="checkbox"/> Undocumented <input type="checkbox"/> Other:			
Patient History/Brief Summary:			
Signs and Symptoms of TB (<i>check all that apply</i>): Earliest onset date: <input type="checkbox"/> Cough: productive/dry <input type="checkbox"/> Loss of Appetite <input type="checkbox"/> Fatigue <input type="checkbox"/> Shortness of Breath <input type="checkbox"/> Weight Loss (>10%) <input type="checkbox"/> Lymph Node Swelling <input type="checkbox"/> Chest Pain <input type="checkbox"/> Fever / Chills Site: _____ <input type="checkbox"/> Hemoptysis <input type="checkbox"/> Night Sweats <input type="checkbox"/> Other: _____			
Medical Risk Factors (<i>check all that apply</i>): <input type="checkbox"/> Diabetes Mellitus <input type="checkbox"/> Leukemia <input type="checkbox"/> End-stage renal disease <input type="checkbox"/> Alcohol Abuse <input type="checkbox"/> Lymphoma <input type="checkbox"/> Organ Transplant <input type="checkbox"/> Tobacco use <input type="checkbox"/> Cancer of head or neck <input type="checkbox"/> Age ≤ 5 years <input type="checkbox"/> Silicosis <input type="checkbox"/> Drug abuse <input type="checkbox"/> Contact to DR-TB case <input type="checkbox"/> Immunosuppressive therapy <input type="checkbox"/> HIV seropositive <input type="checkbox"/> TB test conversion in 2 yrs. <input type="checkbox"/> Gastrectomy or jejunioileal bypass <input type="checkbox"/> Recent exposure to TB <input type="checkbox"/> Other: <input type="checkbox"/> Chronic malabsorption syndromes <input type="checkbox"/> Fibrotic lesions on Chest X-Ray <input type="checkbox"/> Weight <10% ideal body weight consistent with, old, healed TB <input type="checkbox"/> Other medical conditions:			
Risk factors for DR-TB (<i>check all that apply</i>): <input type="checkbox"/> Previous TB treatment <input type="checkbox"/> Previous incomplete and/or inadequate treatment <input type="checkbox"/> Contact to DR-TB; specify: _____ <input type="checkbox"/> Born in/travel to country with DR-TB. Specify: _____			

Diagnostic Information

Radiology

Initial Chest X-Ray Date: <input type="checkbox"/> Normal <input type="checkbox"/> Abnormal <input type="checkbox"/> Cavitory		Initial CT Date: <input type="checkbox"/> Normal <input type="checkbox"/> Abnormal <input type="checkbox"/> Cavitory	
--	--	---	--

Pathology

Pathology Date/Results: <input type="checkbox"/> N/A

Bacteriology/Acid Fast Bacilli (AFB)

Date of Initial AFB Smear: _____	<input type="checkbox"/> Sputum <input type="checkbox"/> Other: _____	<input type="checkbox"/> Pos. <input type="checkbox"/> Neg.
Date of PCR/NAAT: _____	<input type="checkbox"/> Pos. <input type="checkbox"/> Neg. RIF Resistance Detected? <input type="checkbox"/> Y <input type="checkbox"/> N <input type="checkbox"/> Not Tested	
Sputum Smear Conversion date: _____	<input type="checkbox"/> Pending <input type="checkbox"/> N/A	
Date of Initial Positive MTB Culture: _____	Site: <input type="checkbox"/> Sputum <input type="checkbox"/> Other: _____	
Culture Conversion date: _____	<input type="checkbox"/> Pending <input type="checkbox"/> N/A	

Texas Department of State Health Services Drug-Resistant Tuberculosis Monitoring Program

Case Conference Presentation Summary

Molecular Testing	
MDDR result date: _____	MDDR Mutations: _____
rpoB alert date: _____	<input type="checkbox"/> N/A
Drug Susceptibility Testing (DSTs)	
DSTs result date: _____	Resistance on DSTs: _____ <input type="checkbox"/> Pending
Treatment	
RIPE Start Date: _____	RIPE Stop Date: _____
DR-TB Regimen started: <input type="checkbox"/> inpatient (where: _____) <input type="checkbox"/> outpatient	TCID admission: <input type="checkbox"/> Yes <input type="checkbox"/> No Admitted: _____ Discharged: _____
Reason for TCID admission: _____	TCID physician: _____
DR-TB Regimen Start Date: _____ DR-TB Regimen Stop Date: _____ Reason: _____	
Administration: <input type="checkbox"/> DOT <input type="checkbox"/> VDOT Frequency: <input type="checkbox"/> 5x/week <input type="checkbox"/> 7x/week <input type="checkbox"/> 3x/week (specify): _____	
<input type="checkbox"/> INH _____ mg	<input type="checkbox"/> BDQ _____ mg
<input type="checkbox"/> RIF _____ mg	<input type="checkbox"/> Pa _____ mg
<input type="checkbox"/> PZA _____ mg	<input type="checkbox"/> LZD _____ mg
<input type="checkbox"/> EMB _____ mg	<input type="checkbox"/> MFX _____ mg
<input type="checkbox"/> LFX _____ mg	<input type="checkbox"/> CFZ _____ mg
<input type="checkbox"/> CS _____ mg	<input type="checkbox"/> B6 _____ mg
<input type="checkbox"/> Other _____ mg	<input type="checkbox"/> Other _____ mg
Notes: _____	
Treatment interruptions: <input type="checkbox"/> No <input type="checkbox"/> Yes, specify: _____	
Baseline Toxicity Assessments	
Baseline Monthly Toxicity Assessment Date: _____	
<input type="checkbox"/> ECG / Cardiac Monitoring	
<input type="checkbox"/> Normal <input type="checkbox"/> Abnormal QTc: _____	Notes: _____
<input type="checkbox"/> Mental Health Assessment	
<input type="checkbox"/> Normal <input type="checkbox"/> Abnormal Notes: _____	
<input type="checkbox"/> Visual Acuity / Ishihara	
<input type="checkbox"/> Normal <input type="checkbox"/> Abnormal Notes: _____	
<input type="checkbox"/> Peripheral Neuropathy Monitoring	
<input type="checkbox"/> Normal <input type="checkbox"/> Abnormal Notes: _____	
<input type="checkbox"/> Other (i.e. tendon pain, joint pain, emesis, audiometry/vestibular, etc.)	
<input type="checkbox"/> Normal <input type="checkbox"/> Abnormal Notes: _____	
Trends/concerns: _____	
Challenges	
Plan	

Texas Department of State Health Services Drug-Resistant Tuberculosis Monitoring Program Case Conference Presentation Summary

Contact Investigation

Genotype: _____ Match to other DR-TB: Yes No Explain: _____

Consult Done: Yes No *if no, explain:*
 Primary exposure location: _____
 Infectious period start date: _____
 Date first round completed: _____

	Initial
Number of contacts identified	
Number of contacts evaluated	
Number of documented prior positives	
Number of contacts identified with TB infection	
Number of conversions	
Number of contacts eligible for treatment of TB infection	
Number of contacts identified under the age of 5	
Number of contacts under the age of 5 with TB infection	
Number of contacts under the age of 5 on window prophylaxis	
Number of others identified for window prophylaxis (i.e. HIV, etc.)	
Number of contacts <i>currently</i> on treatment for TB infection	
Number of contacts that completed treatment for TB infection	
Number of contacts that did not complete treatment for TB infection	
Number of contacts that refused treatment for TB infection	
Number of contacts identified with TB disease	
Number of contacts under the age of 5 with TB disease	
Percentage of contacts infected (positivity rate)	

CI Findings/Issues/Challenges/Other (Include plan and regimen for contacts and plan for CI completion):

DSHS Internal Notes:

Texas Department of State Health Services Drug-Resistant Tuberculosis Monitoring Program

Case Conference Presentation Summary

Quarterly Updates

Surveillance Event #:	Age/Gender:
Site and Type of Disease: <input type="checkbox"/> Suspected <input type="checkbox"/> Confirmed <input type="checkbox"/> Pulmonary <input type="checkbox"/> Extrapulmonary, site: <input type="checkbox"/> RR <input type="checkbox"/> MDR <input type="checkbox"/> Pre-XDR <input type="checkbox"/> XDR <input type="checkbox"/> Intolerant/Functional ATS Class 3 Date: _____	
Patient History/Brief Summary:	

Updated Information on TB Diagnostics (do not include initial)

Radiology	Bacteriology		Other Diagnostics
Result: _____	Smear conversion date: _____	Culture conversion date: _____	MDDR, DSTs, pathology, other TB diagnostics:
Result: _____	Date: _____	Date: _____	
Result: _____	Date: _____	Date: _____	
Result: _____	Date: _____	Date: _____	
Result: _____	Date: _____	Date: _____	
Result: _____	Date: _____	Date: _____	
Result: _____	Date: _____	Date: _____	

Treatment Updates

DR-TB Regimen started: <input type="checkbox"/> Inpatient (where: _____) <input type="checkbox"/> Outpatient If TCID, date admitted: _____ TCID physician: _____ Date Discharged: _____ Reason for admission: _____			
DR-TB Regimen Start Date: _____ Administration: <input type="checkbox"/> DOT <input type="checkbox"/> VDOT Frequency: <input type="checkbox"/> 5x/week <input type="checkbox"/> 7x/week <input type="checkbox"/> 3x/week (specify): _____ Current Regimen: _____			
Date changed: _____	Changes: _____	Reason: _____	Other: _____
Date changed: _____	Changes: _____	Reason: _____	Other: _____
Date changed: _____	Changes: _____	Reason: _____	Other: _____
Date changed: _____	Changes: _____	Reason: _____	Other: _____
Date changed: _____	Changes: _____	Reason: _____	Other: _____
Other Notes: _____			
Date due to complete therapy: _____		Treatment interruptions: <input type="checkbox"/> No <input type="checkbox"/> Yes, specify: _____	
Date completed therapy: _____			

Texas Department of State Health Services
Drug-Resistant Tuberculosis Monitoring Program
Case Conference Presentation Summary

Toxicity Assessments

(Cardiac, Mental Health, Visual, Peripheral Neuropathy, Other)

Monthly toxicity assessments *have* *have not* been missed. *(If missed discuss the reason and plans to resume):*

Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____
Date: _____	Results: QTc: _____	Other: _____

Notes:

New or Resolved Challenges

Current Patient Care Plan

End of treatment consult submitted Yes No *if No explain why:*
Post-treatment follow-up plan (when known):

Texas Department of State Health Services
Drug-Resistant Tuberculosis Monitoring Program
 Case Conference Presentation Summary

Quarterly Update Contact Investigation

Genotype: _____ Match to other DR-TB: Yes No Explain: _____

Contact investigation completed: Yes No

Primary exposure location: _____

Date second round completed: _____

Present available data below:

	Updates	Final
Number of contacts identified		
Number of contacts evaluated		
Number of documented prior positives		
Number of contacts identified with TB infection		
Number of conversions		
Number of contacts eligible for treatment of TB infection		
Number of contacts identified under the age of 5		
Number of contacts under the age of 5 with TB infection		
Number of contacts under the age of 5 on window prophylaxis		
Number of others identified for window prophylaxis (i.e. HIV, etc.)		
Number of contacts <i>currently</i> on treatment for TB infection		
Number of contacts that completed treatment for TB infection		
Number of contacts that did not complete treatment for TB infection		
Number of contacts that refused treatment for TB infection		
Number of contacts identified with TB disease		
Number of contacts under the age of 5 with TB disease		
Percentage of contacts infected (positivity rate)		

CI Findings/Issues/Challenges/Other (include date a consult was submitted, regimen recommended for contacts on LTBI, plan for contacts (i.e., serial CXRs), status of CI):

DSHS Internal Notes: